Analysts Set OptimizeRx Corp. (NASDAQ:OPRX) Target Price at $10.81

OptimizeRx Corp. (NASDAQ:OPRX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $10.81.

Several equities analysts recently issued reports on OPRX shares. Wall Street Zen upgraded OptimizeRx from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. JMP Securities raised their price objective on OptimizeRx from $11.00 to $14.00 and gave the stock a "market outperform" rating in a research note on Tuesday, May 13th. Stifel Nicolaus raised their price objective on OptimizeRx from $12.50 to $16.00 and gave the stock a "buy" rating in a research note on Monday, June 9th. Citigroup reaffirmed an "outperform" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Finally, Roth Capital reaffirmed a "buy" rating on shares of OptimizeRx in a research report on Tuesday, May 13th.

OptimizeRx Stock Down 0.1%

OptimizeRx stock traded down $0.01 during midday trading on Tuesday, hitting $13.93. The stock had a trading volume of 23,979 shares, compared to its average volume of 372,939. The company has a current ratio of 2.82, a quick ratio of 2.82 and a debt-to-equity ratio of 0.25. The stock has a market cap of $257.71 million, a P/E ratio of -16.56, a P/E/G ratio of 4.59 and a beta of 1.34. OptimizeRx has a 12 month low of $3.78 and a 12 month high of $15.71. The business has a fifty day moving average price of $13.21 and a 200 day moving average price of $9.21.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.19. OptimizeRx had a negative return on equity of 0.29% and a negative net margin of 16.33%. The firm had revenue of $21.93 million for the quarter, compared to analysts' expectations of $18.69 million. Research analysts predict that OptimizeRx will post -0.33 EPS for the current year.

Institutional Trading of OptimizeRx

Several hedge funds have recently added to or reduced their stakes in OPRX. Whetstone Capital Advisors LLC bought a new stake in OptimizeRx during the 4th quarter valued at $6,563,000. Parkman Healthcare Partners LLC bought a new stake in OptimizeRx during the 1st quarter valued at $4,114,000. Invesco Ltd. bought a new stake in OptimizeRx during the 1st quarter valued at $2,542,000. Tang Capital Management LLC bought a new stake in OptimizeRx during the 4th quarter valued at $1,075,000. Finally, Kennedy Capital Management LLC raised its stake in OptimizeRx by 57.8% during the 4th quarter. Kennedy Capital Management LLC now owns 594,000 shares of the company's stock valued at $2,887,000 after acquiring an additional 217,676 shares in the last quarter. Institutional investors own 76.47% of the company's stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.